"Blood pressure drug 'combats' dementia"
Source: The West Australian
Published: 13 Jan 2010
Category: Pharmaceutical
Rating:
(3½ stars)
Keywords: blood, pressure, dementia, alzheimers, angiotensin, receptor, blockers
what they said (Hover the mouse cursor over underlined words for more info)
A widely prescribed drug to tackle high blood pressure and heart disease also appears to reduce the risk of Alzheimer's and other forms of dementia, according to a US study.
The original article can be found at: http://au.news.yahoo.com/thewest/lifestyle/a/-/health/6672979/blood-pressure-drug-combats-dementia/
| Criteria |
Rating |
| Novelty of Treatment |
Satisfactory (?) |
| Availability of Treatment |
Not Satisfactory (?) |
| Treatment Options |
Satisfactory (?) |
| Disease Mongering |
Satisfactory (?) |
| Evidence |
Not Satisfactory (?) |
| Quantification of Benefits of Treatment |
Satisfactory (?) |
| Harms of Treatment |
Not Applicable |
| Costs of Treatment |
Not Satisfactory (?) |
| Sources of Information |
Satisfactory (?) |
| Relies on Press Release |
Not Applicable |
what we said (Hover the mouse cursor over underlined words for more info)
One of the problems with this article is knowing what the halving of risk of admission to a nursing home translates into in terms of an absolute reduction in risk. To be fair, the authors of the scientific paper have not provided details in the published abstract and indeed it is very difficult to dig it out of the full text of the article. The other main criticism is that not enough attention is paid to the fact that the study is not a randomised controlled trial. This is an observational study, meaning that there may be differences between patients receiving the different medications that account for the different rates of dementia, which account for the differences observed. A study like this provides little information on adverse effects of the drugs and costs were not mentioned. The author includes independent commentary, which helps put the results in context.
public forum
There are currently no comments on this article.
|